Research & Development
IQVIA partners with NRx Pharmaceuticals for potential medical support for novel COVID-19 treatment
14 September 2021 -

Advanced analytics company IQVIA (NYSE:IQV) on Monday announced a transformative partnership with NRx Pharmaceuticals (Nasdaq:NRXP), a life-saving treatments company, for the potential medical support for novel COVID-19 treatment, ZYESAMI.

The partners will provide pharmacovigilance services and medical information in preparation for the potential regulatory actions on the US FDA's EUA activation and compliance for ZYESAMI in treating some of the sickest patients suffering from COVID-19.

This agreement provides NRx with access to IQVIA's domain experience with COVID-19, its unparalleled data assets and analytics to support potential emergency use authorization (EUA) of ZYESAMI.

In addition, the companies will support key activities required for US FDA's EUA activation as well as pharmacovigilance and medical information programmes.



Related Headlines